trending Market Intelligence /marketintelligence/en/news-insights/trending/i9sjo1_b8otljhc3h3-5iq2 content esgSubNav
In This List

Shire's constipation treatment accepted for US review

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Shire's constipation treatment accepted for US review

Shire PLC said the U.S. Food and Drug Administration accepted its application for a constipation drug for review.

The Irish biotechnology company is seeking approval for prucalopride, also known as SHP555, to treat chronic idiopathic constipation.

The regulator is expected to make a decision by Dec. 21.

Chronic idiopathic constipation is a common condition affecting nearly one in eight people in the U.S.

Prucalopride is already approved in the European Union and is marketed as Resolor.